MKSAP: 55-year-old man with hepatitis C virus (HCV)

A good MKSAP question is a little like a magician’s trick: it gets you staring at the shiny object while the real answer is hiding in plain sight. This case does exactly that. A 55-year-old man has a positive hepatitis C antibody test, but his HCV RNA is negative and his alanine aminotransferase level is normal. He feels well. His exam is normal. The natural temptation is to order more testing, stare dramatically at the liver, and act as if trouble is tap-dancing on the doorstep. But the smarter move is calmer, simpler, and more evidence-based.

The key lesson is this: a positive HCV antibody test does not automatically mean active hepatitis C infection. In this classic board-style scenario, the most appropriate next step is usually no further testing. The antibody test tells you the immune system has seen HCV at some point. The RNA test tells you whether the virus is currently in the bloodstream. If the antibody is positive but the RNA is not detected, the patient does not have current HCV infection in most cases.

That distinction matters in real life, not just on exams. It prevents unnecessary imaging, avoids repeated lab work that adds cost but little value, and helps clinicians explain results without turning a manageable situation into a medical ghost story. It also reflects how hepatitis C care has evolved: screening is broader, diagnosis is faster, and treatment for active infection is vastly better than it used to be.

The MKSAP takeaway: why “positive antibody, negative RNA” changes the answer

Think of the hepatitis C antibody as a footprint in the snow. It proves someone passed through. It does not prove they are still in the cabin drinking your coffee. HCV RNA is the actual intruder check. If RNA is undetectable, there is no current infection to treat.

In a 55-year-old man with a positive screening antibody test, normal liver enzymes, no symptoms, and no recent risk factors, the board-style answer is straightforward: no further testing. A liver ultrasound is not needed just because the antibody is positive. Serial ALT monitoring is not required when there is no evidence of active infection or liver disease. Repeating the antibody test is especially unhelpful because antibodies can remain positive long after the virus is gone. Repeating HCV RNA is also unnecessary in most stable, low-risk situations.

This is where many test-takers overthink things. Hepatitis C has a reputation for being sneaky, chronic, and potentially serious, which is true. But the test interpretation still follows a clean logic. If there is no detectable virus, there is no current infection. No virus, no active hepatitis C case to chase around the building.

What a positive antibody test actually means

Possible explanation #1: past infection that resolved

Some people are exposed to HCV and later clear the virus. In those cases, the antibody stays positive, but the RNA becomes undetectable. The immune system leaves its business card behind.

Possible explanation #2: biologic false-positive antibody result

Not every reactive antibody test reflects true past infection. That is one reason RNA testing is the essential second step. It sorts history from current reality.

Possible explanation #3: the patient truly has active infection

That only applies when the RNA is detectable. In confirmed active HCV infection, the next steps shift toward staging liver disease, assessing treatment eligibility, and starting direct-acting antiviral therapy.

When “no further testing” is the right answer

For this MKSAP-style patient, no further testing makes sense when all of the following are true: he has a reactive antibody test, undetectable HCV RNA, no signs or symptoms of liver disease, no recent exposure concern, no immunocompromising condition that muddies interpretation, and no specimen-handling concern that would make the RNA result questionable.

In plain English, if the story is quiet and the RNA is negative, do not create a sequel nobody asked for.

When more follow-up would be reasonable

That said, medicine loves exceptions. There are situations where repeating HCV RNA or doing additional evaluation is appropriate. If the patient had a possible exposure within the last 6 months, the RNA may need to be repeated. If he has ongoing risk factors such as injection drug use, a needle exposure, or other blood exposure concerns, follow-up testing may be necessary. If he is immunocompromised, the usual antibody-RNA patterns can be less reliable. And if there are clinical signs of liver disease, abnormal liver tests, or concern about specimen handling, the “do nothing” answer may no longer be the best one.

That is the nuance exam questions are teaching: not every positive screen is an active disease state, but not every negative RNA result should be interpreted in a vacuum either.

Why this old-school board question still matters in modern practice

One reason this case remains useful is that hepatitis C screening has changed. Years ago, a lot of emphasis was placed on screening people born during the baby boomer era and those with classic risk factors. Today, the screening conversation is broader. Clinicians are encouraged to screen adults much more widely, because many people with HCV have no symptoms and do not neatly fit a stereotype.

That matters for a 55-year-old man who feels completely fine. Hepatitis C is often silent until liver damage has been building for years. Routine screening catches people before cirrhosis, liver failure, or liver cancer enters the chat like the world’s least welcome party guest.

It also matters because stigma has long distorted hepatitis C care. Some patients assume a positive test means someone is accusing them of a hidden behavior. Others panic because they hear “positive hepatitis C” and mentally skip straight to transplant talk. Clear interpretation of antibody and RNA testing helps keep the conversation medical, factual, and humane.

How clinicians diagnose active hepatitis C today

Step 1: screen with an HCV antibody test

This identifies whether the person has ever been exposed to the virus.

Step 2: confirm with HCV RNA testing

This determines whether the infection is current and active. Many labs now use reflex testing, which means RNA is automatically run if the antibody is reactive. That saves time and reduces the chance the patient disappears into the mysterious void between “positive screening result” and “please come back for one more tube of blood.”

Step 3: if RNA is positive, evaluate before treatment

For patients with detectable HCV RNA, clinicians assess fibrosis or cirrhosis, review medications for drug interactions, check for hepatitis B and HIV, and determine whether a simplified treatment approach is appropriate.

If the RNA had been positive: what would happen next?

If this 55-year-old man had a detectable HCV RNA level, the tone of the visit would change from reassurance to action. The good news is that action is now much more effective than it was in the interferon era, when hepatitis C treatment sounded like a side-effect contest nobody wanted to win.

Current direct-acting antiviral therapy is usually oral, short-course, and highly effective. Many treatment-naive adults without cirrhosis can be treated with simplified pangenotypic regimens such as glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks. Cure rates are typically above 95%, which is one of the better glow-ups in modern medicine.

Before treatment begins, clinicians also stage liver disease. A liver biopsy is no longer routinely required. Tools such as the FIB-4 score, elastography, platelet count, and imaging findings help estimate whether cirrhosis is present. That matters because cirrhosis changes follow-up, surveillance, and sometimes treatment planning.

Why staging still matters in hepatitis C

Even in the era of simplified treatment, staging is not busywork. It tells you who can be managed with a streamlined approach and who needs specialist input. Patients with decompensated cirrhosis, suspected hepatocellular carcinoma, prior treatment failure, transplant history, hepatitis B surface antigen positivity, or other complicating features do not belong in the one-size-fits-most lane.

And for patients with cirrhosis, long-term follow-up remains important even after cure. Hepatocellular carcinoma surveillance with liver ultrasound, with or without alpha-fetoprotein, is generally recommended every 6 months. In contrast, noncirrhotic patients who achieve virologic cure generally do not need routine liver-related follow-up unless another liver disease or new risk factor enters the picture.

Symptoms, complications, and why early detection matters

Hepatitis C can be oddly quiet for a condition capable of causing real harm. Many people with chronic HCV have no symptoms or only vague complaints such as fatigue. When symptoms do appear, they may include jaundice, nausea, dark urine, abdominal discomfort, poor appetite, or other signs of liver injury. Untreated chronic infection can lead to fibrosis, cirrhosis, liver failure, and liver cancer.

HCV can also show up outside the liver. Clinicians may see extrahepatic problems such as mixed cryoglobulinemia, glomerulonephritis, porphyria cutanea tarda, diabetes, and certain lymphoproliferative disorders. In other words, hepatitis C does not always stay politely in its lane.

Common mistakes this case helps you avoid

Ordering imaging too early

A liver ultrasound is not the first move in a patient with positive antibody, negative RNA, and no evidence of liver disease. That is using the flashlight after you have already established the room is empty.

Repeating the antibody test

This adds confusion, not clarity. Once positive, the antibody may remain positive for years or even for life. It is not a useful marker of cure versus active infection.

Confusing exposure with current infection

Antibody means “has met HCV.” RNA means “HCV is here right now.” Those are not the same clinical situation.

Forgetting the exposure window

If recent exposure is plausible, timing matters. A negative RNA result may need repeat testing in the right context.

Overlooking alcohol and liver health counseling

Even though this particular patient does not have active HCV infection, patients with liver disease risk factors still benefit from counseling about alcohol, vaccination, and healthy follow-up habits.

The patient conversation: how to explain the result without causing panic

A calm explanation goes a long way. You might tell the patient: “Your screening test shows that your body has seen hepatitis C before, but the follow-up RNA test shows there is no active virus in your blood. In most cases, that means you do not have current hepatitis C infection and you do not need treatment.”

Then you add the nuance: if there was a recent exposure, if new risk develops, or if liver-related symptoms appear, follow-up can be reconsidered. Patients appreciate honesty without drama. Most people do not need a TED Talk; they need one clear sentence and permission to exhale.

What this MKSAP case teaches beyond the test answer

The best lesson here is not just the correct multiple-choice option. It is a clinical habit: interpret tests in sequence, not in isolation. Screening is the front door. Confirmation is the lock. Management depends on what is actually inside the house.

For hepatitis C, that means reactive antibody plus detectable RNA equals current infection and treatment evaluation. Reactive antibody plus undetectable RNA usually means no current infection and no further testing in most cases. That is elegant, practical, and easy to remember once you stop letting the word “positive” do all the emotional heavy lifting.

So yes, this 55-year-old man with a positive HCV antibody test deserves attention, but not alarm. The correct next step is restraint, and in medicine, that is sometimes the hardest flex of all.

Experiences related to the topic: what this case feels like in real life

Cases like this are memorable because the lab result often lands before the explanation does. A patient logs into a portal, sees the word positive, and the mind starts sprinting. Some people immediately worry about liver cancer. Some worry about how they could have gotten hepatitis C. Some worry that a spouse will misunderstand the result. By the time they walk into clinic, they have already had a full emotional season finale.

That is why the follow-up conversation matters so much. In practice, many patients feel enormous relief when they learn that a positive antibody and negative RNA result usually means no current infection. The relief is often physical. Shoulders drop. Breathing slows. The patient who arrived braced for terrible news suddenly wants to know the practical stuff instead: “So I do not need treatment?” “Can I still donate blood?” “Will this always show up on tests?” “Do I need to tell every doctor forever?”

Clinicians also learn that hepatitis C is wrapped in old stigma. A patient may say, “But I never used drugs,” because they assume the test result is also a judgment. Others may have a remote transfusion history, an old medical exposure, or no obvious story at all. The experience of discussing HCV is often less about virology and more about restoring perspective. The doctor is not just interpreting a lab value; the doctor is also untangling fear, shame, and misinformation.

For patients with active HCV infection, the experience can be surprisingly different from what they expected. Many still imagine treatment as a long, miserable ordeal because they remember older stories about interferon. Instead, they learn that modern treatment is usually a short course of pills with excellent cure rates and far fewer side effects. The emotional shift can be dramatic. Hepatitis C stops sounding like a life sentence and starts sounding like a problem with a plan.

There is also a practical side to the experience. Patients need help understanding why fibrosis staging matters, why medication reconciliation is important, and why a cure does not mean immunity. Some are surprised to learn that even after successful treatment, the antibody test may stay positive. That can be confusing unless someone explains the difference between an immune footprint and active virus. It is one of those medical details that becomes simple only after a human being explains it like a human being.

From the clinician side, this topic is a reminder that reassurance should be precise, not casual. “You are fine” is less helpful than “You do not have current hepatitis C infection based on an undetectable RNA test, and in most cases no more testing is needed unless there was recent exposure or another concern.” Precision builds trust. It also prevents the patient from going home and asking the internet, which is how a calm follow-up visit turns into a 2 a.m. spiral involving five tabs and one very dramatic forum post from 2008.

In that sense, the real experience of this MKSAP case is not just about getting the answer right. It is about learning how good medicine sounds when it is accurate, clear, and kind. That is the part patients remember long after the lab values stop being scary.

Note: This article is for educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment.